Puma Biotechnology Barclays Global Healthcare Conference March 2021 Forward-Looking Safe-Harbor Statement This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director of Investor Relations Alan Auerbach – President, Chairman and Chief Executive Officer Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Kennen MacKay – RBC Capital Markets Kenneth Atkins – Cowen Turner Kufe – J.P. Morgan Alec Stranahan – Bank of America Charles Ferranti – Goldman Sachs Operator ...

Background Results HER2 activation results in enhanced tumor growth in preclinical models Aberrant HER2 activation HER2 amplification or overexpressionHER2 (ERBB2) somatic mutations P P P P P P P P P Activation of downstream signal transduction pathways Subset of HER2 mutations result in constitutive kinase signaling, oncogenic transformation and enhanced tumor growth in preclinical models1 Biliary tract cancer and HER2 mutations Biliary tract cancer is a heterogeneous and rare disease with poor prognosis; ...

Financial Performance - Net NERLYNX revenue reached approximately $49.3 million in Q3 2020[10] - Approximately 3,600 ex-factory bottles of NERLYNX were sold in Q3 2020[15] NERLYNX Usage - Around 33% of patients in Q3 2020 started NERLYNX at a reduced dose (fewer than 6 pills per day)[18, 20] Global Expansion & Regulatory Milestones - Australia/SE Asia: Approved in Australia (March 2019), Singapore (December 2019), Brunei, Malaysia, New Zealand (Q2/Q3 2020)[23] - Israel: Launched in Q1 2020; Approved for metastatic breast cancer in Q3 2020[24] - Canada: Approved in July 2019; Metastatic sNDS accepted by HC in September 2020[24] - Greater China: Approved in Hong Kong (November 2019), China (April 2020), and Taiwan (August 2020)[24] - Latin America: Launched in Argentina (Q1 2020); Approved in Chile (Q2 2020) and Ecuador (Q3 2020); Expecting approvals in Brazil, Colombia, Mexico, and Peru in 2021[25] - Europe: Launched in Germany, United Kingdom, and Austria (Q4 2019); Launched in Sweden and approved in Switzerland (Q1 2020); Planned launch in Finland (Q4 2020)[26] - South Korea: NDA filed in October 2020[28]

Puma Biotechnology, Inc. (PBY) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Chief Executive Officer, President, and Chairman of the Board Jeff Ludwig – Chief Commercial Officer Maximo Nougues – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright & Company Samantha Semenkow – Citi Kennen MacKay – RBC Capital Markets Laura Christianson – Cowen and Company Operator Greetings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State or other jurisdiction ...

Puma Biotechnology Earnings Call Commercial Update 1 August 6, 2020 Forward-Looking Safe Harbor Statement 2 This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward– looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. ("Puma"). Forward–looking statements involve risks and uncertainties ...

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Chief Executive Officer, President & Chairman of the Board Jeff Ludwig - Chief Commercial Officer Maximo Nougues - Chief Financial Officer Conference Call Participants Samantha Semenkow - Citigroup Paul Choi - Goldman Sachs Operator Good afternoon. My name is Jesse, and I will be your conference call operator today. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 77-0683487 (I.R.S. Employer Identification Number) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition peri ...